Atrion (NASDAQ:ATRI) Sees Unusually-High Trading Volume

Shares of Atrion Co. (NASDAQ:ATRI) saw strong trading volume on Monday . 14,391 shares changed hands during mid-day trading, a decline of 23% from the previous session’s volume of 18,792 shares.The stock last traded at $418.86 and had previously closed at $414.95.

Analyst Ratings Changes

Separately, StockNews.com lowered shares of Atrion from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st.

Atrion Stock Performance

The company has a fifty day simple moving average of $412.89 and a two-hundred day simple moving average of $365.51. The stock has a market capitalization of $765.60 million, a price-to-earnings ratio of 37.62 and a beta of 0.62.

Atrion (NASDAQ:ATRI) last issued its quarterly earnings results on Thursday, February 29th. The medical instruments supplier reported $3.65 EPS for the quarter. Atrion had a return on equity of 8.07% and a net margin of 11.46%. The company had revenue of $43.58 million for the quarter.

Atrion Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, March 29th. Stockholders of record on Friday, March 15th were given a $2.20 dividend. This represents a $8.80 annualized dividend and a dividend yield of 2.02%. The ex-dividend date of this dividend was Thursday, March 14th. Atrion’s payout ratio is presently 79.78%.

Institutional Trading of Atrion

Several large investors have recently made changes to their positions in ATRI. Copeland Capital Management LLC raised its position in Atrion by 56.4% during the fourth quarter. Copeland Capital Management LLC now owns 86 shares of the medical instruments supplier’s stock valued at $33,000 after purchasing an additional 31 shares in the last quarter. Quadrant Capital Group LLC bought a new position in shares of Atrion in the 4th quarter valued at $36,000. Harbor Investment Advisory LLC raised its holdings in shares of Atrion by 33.1% during the 4th quarter. Harbor Investment Advisory LLC now owns 189 shares of the medical instruments supplier’s stock worth $72,000 after buying an additional 47 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Atrion by 592.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 270 shares of the medical instruments supplier’s stock worth $102,000 after buying an additional 231 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new stake in Atrion in the fourth quarter valued at about $108,000. Institutional investors and hedge funds own 66.19% of the company’s stock.

About Atrion

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.